NEW YORK, May 14, 2012 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index® (Nasdaq:NBI), which will become effective prior to market open on Monday, May 21, 2012.
The following ten securities will be added to the Index: Cerus Corporation (Nasdaq:CERS), Celldex Therapeutics, Inc. (Nasdaq:CLDX), Amicus Therapeutics, Inc.(Nasdaq:FOLD), Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), Jazz Pharmaceuticals plc (Nasdaq:JAZZ), Omeros Corporation (Nasdaq:OMER), Orexigen Therapeutics, Inc. (Nasdaq:OREX), Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX), Raptor Pharmaceutical Corp. (Nasdaq:RPTP) and Trius Therapeutics, Inc. (Nasdaq:TSRX).
The Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November. For more information about the NASDAQ Biotechnology Index, including detailed eligibility criteria, visit https://indexes.nasdaqomx.com/.
As a result of the re-ranking, the following five securities will be removed from the Index: BioSante Pharmaceuticals, Inc. (Nasdaq:BPAX), China Biologic Products, Inc. (Nasdaq:CBPO), Columbia Laboratories, Inc. (Nasdaq:CBRX), Cardiome Pharma Corp (Nasdaq:CRME) and DURECT Corporation (Nasdaq:DRRX).
The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology IndexSM Fund (Nasdaq:IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the NASDAQ Biotechnology Index and the iShares Nasdaq Biotechnology Index Fund trade on various exchanges.